Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.10.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Operating Costs and Expenses:        
General and administrative $ 1,474 $ 1,705 $ 4,525 $ 5,440
Research and development 2,846 4,137 9,788 15,028
Total Operating Costs and Expenses 4,320 5,842 14,313 20,468
Loss from Operations (4,320) (5,842) (14,313) (20,468)
Other Income (Expense):        
Change in fair value of warrant liability 626 (5,092) 4,064 2,157
Interest income 5 4 20 7
Total Other Income (Expense) 631 (5,088) 4,084 2,164
Net Loss (3,689) (10,930) (10,229) (18,304)
Net Loss Attributable to Non-controlling Interest (9) (8) (35) (280)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (3,680) (10,922) (10,194) (18,024)
Series A Preferred Stock Dividends (61) (6,901) (181) (6,901)
Net Loss Attributable to Common Stock Holders $ (3,741) $ (17,823) $ (10,375) $ (24,925)
Net Loss Per Share - Basic and Dilutive $ (0.93) $ (4.90) $ (2.73) $ (7.00)
Weighted average number of shares outstanding during the period - Basic and Dilutive 4,028,304 3,665,134 3,802,812 3,512,868